title: Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms.
abstract: Expression of apoptosis-related proteins, bcl-2, Bax, Fas and Fas ligand (L), in ovarian epithelial neoplasms together with its clinical relevance was examined by immunohistochemistry. They included 36 cases with adenoma, 33 with low potential malignancy (LPM) and 63 with carcinomas. bcl-2 expression was observed in 14 of 36 cases (39%) with adenoma, five of 33 (15%) with LPM (P< 0.05) and 12 of 63 (19%) with carcinoma (P < 0.05). Cases with bcl-2 expression showed more favourable prognosis than those without, but the difference was not statistically significant. There was no difference in frequency of Bax and Fas expression between each histologic category. Fas L expression was observed in one of 36 cases (3%) with adenoma, but in 12 of 33 (36%) with LPM (P < 0.001) and 42 of 63 (67%) with carcinoma (P < 0.0001). In carcinomas, cases expressing Fas L showed a less favourable prognosis than those without (P = 0.02). Density of CD8+ lymphocytes, possibly cytotoxic T-cells, was higher in serous carcinoma with negative Fas L expression than those with positive Fas L expression. These findings suggest that Fas L expressing carcinomas induce apoptosis in infiltrating CTL with Fas expression, and escape from immune surveillance.
authors.affiliation: Department of Pathology, Osaka University Medical School, Suita, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Munakata
authors.forename: T
authors.initials: T
authors.lastname: Enomoto
authors.forename: M
authors.initials: M
authors.lastname: Tsujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Otsuki
authors.forename: H
authors.initials: H
authors.lastname: Miwa
authors.forename: H
authors.initials: H
authors.lastname: Kanno
authors.forename: K
authors.initials: K
authors.lastname: Aozasa
mesh_terms: D000236:Adenoma / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D017209:Apoptosis; D002277:Carcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D053222:Fas Ligand Protein; D005260:Female; D019254:Genes, bcl-2; D006801:Humans; D007150:Immunohistochemistry; D016246:Lymphocytes, Tumor-Infiltrating; D008562:Membrane Glycoproteins / Q000032:analysis / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis / Q000235:genetics; D016019:Survival Analysis; D051028:bcl-2-Associated X Protein; D019014:fas Receptor
chemical_list: C494826:BAX protein, human; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D019014:fas Receptor